Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole

Investigational New Drugs

Volumn 31, Issue 2, 2013, Pages 381-389

  Devriese, L A ^a   Mergui Roelvink, M ^a   Wanders, J ^b   Jenner, A ^b   Edwards, G ^b   Reyderman, L ^c   Copalu, W ^b   Peng, F ^c   Marchetti, S ^a   Beijnen, J H ^d,e   Schellens, J H M ^a,d  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b EISAI CO LTD   (Japan)

^c EISAI INC   (United States)

^d UTRECHT UNIVERSITY   (Netherlands)

^e SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

CYP3A4 induction; Drug drug interaction; Eribulin mesylate; Ketoconazole; Microtubule dynamics inhibitor; Pharmacokinetics

Indexed keywords

CYTOCHROME P450 3A4; ERIBULIN; KETOCONAZOLE;

ADENOCARCINOMA; ADULT; AGED; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; CYP3A4 GENE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ERUPTION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; FATIGUE; FEMALE; GENE; HUMAN; ILEUS; LACRIMATION; LACRIMATION DISORDER; LUNG CARCINOMA; MALE; MAXIMUM PLASMA CONCENTRATION; MELANOMA; MESOTHELIOMA; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SENSORY NEUROPATHY; SIDE EFFECT; SIGMOID CARCINOMA; SINGLE DRUG DOSE; SOLID TUMOR; STOMATITIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; XEROSTOMIA;

ADMINISTRATION, ORAL; AGED; ANTIFUNGAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; FURANS; HUMANS; INFUSIONS, INTRAVENOUS; KETOCONAZOLE; KETONES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PROGNOSIS; TISSUE DISTRIBUTION;

EID: 84879555346     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-012-9829-3     Document Type: Article

References (30)

1. Dresser GK, Spence JD, Bailey DG (2000) Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38:41-57
2. Towle MJ, Salvato KA, Budrow J, Wels BF, Kuznetsov G, Aalfs KK, Welsh S, Zheng W, Seletsk BM, Palme MH, Habgood GJ, Singer LA, Dipietro LV, Wang Y, Chen JJ, Quincy DA, Davis A, Yoshimatsu K, Kishi Y, Yu MJ, Littlefield BA (2001) In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 61:1013-1021
3. Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, Littlefield BA, Wilson L (2005) The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 4:1086-1095
4. Okouneva T, Azarenko O, Wilson L, Littlefield BA, Jordan MA (2008) Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther 7:2003-2011
5. Smith JA, Wilson L, Azarenko O, Zhu X, Lewis BM, Littlefield BA, Jordan MA (2010) Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry 49:1331-1337
6. Twelves C, Cortes J, Vahdat LT, Wanders J, Akerele C, Kaufman PA (2010) Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clin Breast Cancer 10:160-163
7. U.S.National Institute of Health. http://www.clinicaltrials.gov. Accessed on 26 April 2011
8. Vahdat LT, Pruitt B, Fabian CJ, Rivera RR, Smith DA, Tan-Chiu E, Wright J, Tan AR, Dacosta NA, Chuang E, Smith J, O'Shaughnessy J, Shuster DE, Meneses NL, Chandrawansa K, Fang F, Cole PE, Ashworth S, Blum JL (2009) Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 27:2954-2961
9. Cortes J, Vahdat L, Blum JL, Twelves C, Campone M, Roche H, Bachelot T, Awada A, Paridaens R, Goncalves A, Shuster DE, Wanders J, Fang F, Gurnani R, Richmond E, Cole PE, Ashworth S, Allison MA (2010) Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 28:3922-3928
10. Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Dieras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C (2011) Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377:914-923
11. Goel S, Mita AC, Mita M, Rowinsky EK, Chu QS, Wong N, Desjardins C, Fang F, Jansen M, Shuster DE, Mani S, Takimoto CH (2009) A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res 15:4207-4212
12. Tan AR, Rubin EH, Walton DC, Shuster DE, Wong YN, Fang F, Ashworth S, Rosen LS (2009) Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res 15:4213-4219
13. Zhang ZY, King BM, Pelletier RD, Wong YN (2008) Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4. Cancer Chemother Pharmacol 62:707-716
14. Reyderman L, Gupta A, Pelletier R, Wong N: Eribulin and cytochrome P450 effectors: in vitro studies and population pharmacokinetic-pharmacodynamic analysis. Abstract 573 presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Therapeutics, Berlin, Germany, November 16-19 2010
15. European Medicines Agency Committee for medicinal products for human use (CHMP); Guideline on the investigation of drug interactions CPMP/EWP/560/95/Rev. 1-Corr. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific- guideline/2010/05/WC500090112.pdf. 2010
16. U.S.Food and Drug Administration; Guidance for industry. In vivo drug metabolism/drug interaction studies - study design, data analysis, and recommendations for dosing and labeling http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM072119.pdf. 1999
17. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655
18. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41
19. Summary of products characteristics for Nizoral. http://www.medicines. org.uk/emc/document.aspx?documentId=912. 2010
20. Summary of products characteristics for Halaven. http://www.ema.europa. eu/docs/en-GB/document-library/EPAR-Product-Information/human/002084/ WC500105112.pdf. 2011
21. Cancer Therapy Evaluation Program NCI Common Terminology Criteria AE Version 3.0 (NCI-CTCAE v3.0). 2006
22. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
23. Dubbelman AC, Rosing H, Thijssen B, Lucas L, Copalu W, Wanders J, Schellens JH, Beijnen JH (2011) Validation of high-performance liquid chromatography-tandem mass spectrometry assays for the quantification of eribulin (E7389) in various biological matrices. J Chromatogr B Analyt Technol Biomed Life Sci 879:1149-1155
24. Engels FK, Ten Tije AJ, Baker SD, Lee CK, Loos WJ, Vulto AG, Verweij J, Sparreboom A (2004) Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin Pharmacol Ther 75:448-454
25. Kehrer DF, Mathijssen RH, Verweij J, de Bruijn P, Sparreboom A (2002) Modulation of irinotecan metabolism by ketoconazole. J Clin Oncol 20:3122-3129
26. 14C-eribulin in patients with advanced solid tumours. Drug Metab Dispos 40:313-321
27. Goel S, Cohen M, Comezoglu SN, Perrin L, Andre F, Jayabalan D, Iacono L, Comprelli A, Ly VT, Zhang D, Xu C, Humphreys WG, McDaid H, Goldberg G, Horwitz SB, Mani S (2008) The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development. Clin Cancer Res 14:2701-2709
28. Lee CA, Cook JA, Reyner EL, Smith DA (2010) P-glycoprotein related drug interactions: clinical importance and a consideration of disease states. Expert Opin Drug Metab Toxicol 6:603-619
29. Taur JS, Desjardins CS, Schuck EL, Wong YN (2010) Interactions between the chemotherapeutic agent eribulin mesylate (E7389) and P-glycoprotein in CF-1 abcb1a-deficient mice and Caco-2 cells. Xenobiotica 41:320-326
30. Wang EJ, Lew K, Casciano CN, Clement RP, Johnson WW (2002) Interaction of common azole antifungals with P glycoprotein. Antimicrob Agents Chemother 46:160-165